Researchers one step closer to countering deadly Nipah virus

An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences and three groups within the National Institutes of Health reports a new breakthrough in countering the deadly Nipah virus. The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for Nipah that has the potential for human therapeutic applications.

Nipah and the closely related Hendra are highly infectious agents that emerged from Pteropid fruit bats in the 1990s, causing serious disease outbreaks in a variety of domestic animals and humans in Australia, Malaysia, Singapore, Bangladesh and India. Recent Nipah outbreaks have resulted in acute respiratory distress syndrome and encephalitis, person-to-person transmission and greater than 90 percent fatality rates among people. These properties make both Nipah and Hendra viruses a concern to human and livestock health.

Previous studies conducted by these researchers have found that the patented m102.4 could protect from a deadly Hendra infection. In a paper appearing in Science Translational Medicine on June 25, the group describes the therapy that protected nonhuman primates from disease at several time points after Nipah exposure, including the onset of clinical illness in this lethal disease.

"What makes this study unique is that we have achieved complete protection against death even in animals that received treatment five days after being infected with the Nipah virus when they otherwise would have succumbed within 8-10 days of infection," according to UTMB professor Thomas Geisbert, first author of the paper. "This recent success of the antibody therapy against Nipah virus disease in a nonhuman primate is a key step towards its development as a therapeutic for use in people."

Christopher Broder, USU professor and Geisbert's fellow senior author, stated that because of the new data and previous work with this antibody with Hendra virus experiments, "there was sufficient interest for the Queensland government in Australia to initiate a phase I clinical safety trial with m102.4 that is set to commence later this year."

More information: "Therapeutic Treatment of Nipah Virus Infection in Nonhuman Primates with a Neutralizing Human Monoclonal Antibody," by T.W. Geisbert et al. stm.sciencemag.org/lookup/doi/… scitranslmed.3008929

add to favorites email to friend print save as pdf

Related Stories

Major advance in the treatment of Hendra virus reported

Oct 19, 2011

A collaborative research team from Boston University School of Medicine (BUSM), the Uniformed Services University of the Health Sciences (USU), the University of Texas Medical Branch (UTMB) and Galveston National ...

Test vaccine successfully protects monkeys from Nipah virus

Aug 08, 2012

Researchers have successfully tested in monkeys a vaccine against Nipah virus, a human pathogen that emerged in 1998 during a large outbreak of infection and disease among pigs and pig farmers in Southeast Asia. This latest ...

Griffith University tackles deadly Hendra virus

Jun 04, 2012

Australian medical researchers are on the brink of an effective human treatment for the deadly Hendra virus, and potentially the closely related Nipah virus, which has killed more than two hundred people in South East Asia.

New bat virus could hold key to Hendra virus

Aug 02, 2012

Australian scientists have discovered a new virus in bats that could help shed light on how Hendra and Nipah viruses cause disease and death in animals and humans. The new virus - named 'Cedar' after the Queensland ...

Recommended for you

Oral contraceptive equal to antibiotics for acne care

6 hours ago

(HealthDay)—At six months, oral contraceptive pills (OCPs) are comparable to systemic antibiotics for acne management, according to a review published in the September issue of the Journal of the American Ac ...

Photodynamic therapy vs. cryotherapy for actinic keratoses

8 hours ago

Photodynamic therapy (PDT, which uses topical agents and light to kill tissue) appears to better clear actinic keratoses (AKs, a common skin lesion caused by sun damage) at three months after treatment than cryotherapy (which ...

US official warns Ebola outbreak will get worse

9 hours ago

A third top doctor has died from Ebola in Sierra Leone, a government official said Wednesday, as a leading American health official warned that the outbreak sweeping West Africa would get worse before it ...

UN releases $1.5mn to help DR Congo fight Ebola

11 hours ago

The United Nations on Wednesday allocated $1.5 million (1.1 million euros) to help the Democratic Republic of Congo fight Ebola, just days after the country confirmed its first cases this year.

User comments